News Tesaro's Zejula primed for EU approval, battle with AZ EU regulators recommend PARP inhibitor Zejula
News Rubraca outshines rivals in ovarian cancer maintenance thera... Clovis' Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.
News Clovis and BMS combine cancer drugs in late-stage trials Clovis and BMS research small molecule and antibody combination.
News Tesaro's niraparib approved in ovarian cancer Company nabs maintenance therapy use, but problems on breast cancer trial.
News AZ's Lynparza impresses with new ovarian cancer data UK firm lays down the gauntlet in the PARP inhibitor battle.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
